Filtered By:
Drug: Estradiol
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6 results found since Jan 2013.
Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas
Obstet Gynecol. 2023 May 1;141(5):901-910. doi: 10.1097/AOG.0000000000005145. Epub 2023 Apr 5.ABSTRACTUterine leiomyomas are common hormone-responsive neoplasms that frequently cause heavy menstrual bleeding, anemia, pelvic pressure, pain, and adverse reproductive outcomes. In this overview, the efficacy and safety of oral gonadotropin-releasing hormone (GnRH) antagonists, co-administered with menopausal replacement-level steroid hormones or used at doses to avoid complete hypothalamic suppression, are reviewed for the management of uterine leiomyomas. Oral GnRH antagonists provide rapid suppression of sex steroids and avo...
Source: Obstetrics and Gynecology - April 27, 2023 Category: OBGYN Authors: Michael F Neblett Elizabeth A Stewart Source Type: research
